Autoimmune connective tissue diseases and other autoinflammatory disorders encompass a spectrum of rare and challenging conditions that frequently present with dermatologic findings, are often associated with systemic comorbidities, and can have a tremendous impact on quality of life. These diseases rarely have FDA-approved therapies.
Goals of the Connective Tissue & Autoinflammatory Disorders Focused Study Group include improving our understanding of the pathogenesis, prognosis, and comorbidities of these conditions, identifying more reliable monitoring tools, and advancing therapeutic options for our patients.
The Connective Tissue & Autoinflammatory Focused Study Group is chaired by Heather Brandling-Bennett, MD at the University of Washington. Contact us if you’re interested in getting involved!
Ramien, Michele, et al. “Blistering severe cutaneous adverse reactions in children: Proposal for pediatric-focused clinical criteria” British Journal of Dermatology (2021).
Chiu, Yvonne, et al. “Body site distribution of pediatric-onset morphea and association with extracutaneous manifestations” Journal of the American Academy of Dermatology (2021).
Reynolds, Sean, et al. “Systemic Immunosuppressive Therapy for Inflammatory Skin Diseases in Children: Expert-Consensus-Based Guidance for Clinical Decision Making During the COVID-19 Pandemic” Pediatric Dermatology (2020).
Arkin, Lisa, et al. “Practice-Based Differences in Pediatric Discoid Lupus Erythmatosus.” British Journal of Dermatology (2019).